Cencora (COR) Surges on Q1 Beat and Raised FY2026 Guidance

Cencora (NYSE:COR) closed higher by 7.1% after reporting first-quarter results that exceeded profit expectations and raised full-year guidance. The company posted adjusted EPS of $4.08, beating estimates of $4.04, while revenue of $85.93B略低于 the $86.03B median forecast. Management raised its 2026 revenue growth guidance to 7%–9% and operating income growth to 11.5%–13.5%, citing strong execution and the completion of the OneOncology acquisition. The stock is not highly volatile, with only two moves exceeding 5% in the past year. It gained 4.3% YTD and is near its 52-week high of $374.75 at $353.35/share. Sector-level optimism, including a 13%–16% EPS growth target raised by McKesson, contributed to broader confidence in the pharmaceutical distribution space.